Cytokinetics, Incorporated (NASDAQ:CYTK) had its price target lowered by HC Wainwright from $26.00 to $17.00 in a research report report published on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

CYTK has been the topic of a number of other reports. TheStreet cut shares of Cytokinetics, from a c rating to a d rating in a report on Friday, October 27th. Zacks Investment Research upgraded shares of Cytokinetics, from a hold rating to a buy rating and set a $15.00 price target on the stock in a report on Monday, August 7th. ValuEngine upgraded shares of Cytokinetics, from a sell rating to a hold rating in a report on Friday, September 1st. Needham & Company LLC restated a buy rating and issued a $22.00 price target on shares of Cytokinetics, in a report on Sunday, October 29th. Finally, Morgan Stanley restated an overweight rating and issued a $25.00 price target (up from $24.00) on shares of Cytokinetics, in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. Cytokinetics, has an average rating of Buy and an average target price of $18.36.

Cytokinetics, (CYTK) opened at $8.25 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 7.60 and a quick ratio of 7.60. Cytokinetics, has a 1-year low of $7.00 and a 1-year high of $17.20.

Cytokinetics, (NASDAQ:CYTK) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. Cytokinetics, had a negative net margin of 172.27% and a negative return on equity of 62.64%. The company had revenue of $6.18 million for the quarter, compared to analysts’ expectations of $5.35 million. equities analysts forecast that Cytokinetics, will post -2.4 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/cytokinetics-incorporated-cytk-given-new-17-00-price-target-at-hc-wainwright/1719451.html.

In other news, insider Caryn Gordon Mcdowell sold 13,181 shares of Cytokinetics, stock in a transaction that occurred on Friday, October 6th. The shares were sold at an average price of $15.49, for a total transaction of $204,173.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of Cytokinetics, stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $14.71, for a total transaction of $73,550.00. Following the transaction, the chief executive officer now directly owns 79,785 shares of the company’s stock, valued at $1,173,637.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 178,223 shares of company stock valued at $2,639,239. Insiders own 7.20% of the company’s stock.

Several large investors have recently bought and sold shares of CYTK. Janus Henderson Group PLC purchased a new position in shares of Cytokinetics, during the 2nd quarter valued at approximately $32,488,000. Vanguard Group Inc. increased its holdings in shares of Cytokinetics, by 59.9% during the 2nd quarter. Vanguard Group Inc. now owns 3,117,496 shares of the biopharmaceutical company’s stock valued at $37,721,000 after purchasing an additional 1,168,151 shares in the last quarter. Pinnacle Associates Ltd. purchased a new position in shares of Cytokinetics, during the 3rd quarter valued at approximately $14,628,000. State Street Corp increased its holdings in shares of Cytokinetics, by 79.6% during the 2nd quarter. State Street Corp now owns 1,674,335 shares of the biopharmaceutical company’s stock valued at $20,259,000 after purchasing an additional 741,909 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of Cytokinetics, by 128.9% during the 2nd quarter. Acadian Asset Management LLC now owns 766,263 shares of the biopharmaceutical company’s stock valued at $9,271,000 after purchasing an additional 431,457 shares in the last quarter. 71.92% of the stock is owned by hedge funds and other institutional investors.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.